Cambrex has entered into a definitive agreement to acquire Avista Pharma Solutions for roughly $252 million. Avista is a portfolio company of Ampersand Capital Partners. With this acquisition, Cambrex will enter the large and growing market for early stage small molecule development and testing services. Avista offers a broad suite of services ranging from API and drug product development and cGMP manufacturing to stand-alone analytical, microbiology testing and solid state sciences.   “We are...